TEVA Dec 2024 19.000 call
| Previous close | 0.8300 |
| Open | 0.8100 |
| Bid | 0.7800 |
| Ask | 0.8500 |
| Strike | 19.00 |
| Expiry date | 2024-12-20 |
| Day's range | 0.7900 - 0.8300 |
| Contract range | N/A |
| Volume | |
| Open interest | 27.93k |
GlobeNewswireTeva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 TD is an involuntary movement disorder that develops in around 15%-25% of patients taking antipsychotic medications for conditions such as schizophrenia, bipolar disorder, and major depressive disorder2,3 Data presented at the European College of Neuropsychopharmacology Congress (ECNP) in Milan 21-24 September 2024 TE
- GlobeNewswire
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749Currently, there is no long-acting olanzapine treatment option available for the treatment of schizophrenia that does not contain a boxed warning for Post-Injection Delirium/Sedation Syndrome (PDSS)New Phase 3 SOLARIS and Phase 1 safety data show no incidence of PDSS in study participants receiving TEV-‘749 to date TEL AVIV, Israel
- GlobeNewswire
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and decisions for patients and HCPsNew data demonstrate switching to UZEDY at four weeks after the last dose of once-monthly RBP-7000 provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identifiedNew ADVANCE survey findings highlight key patien
